140 related articles for article (PubMed ID: 38133643)
1. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study.
Shah VN; Kanapka LG; Akturk HK; Polsky S; Forlenza GP; Kollman C; Beck RW; Snell-Bergeon JK
Diabetes Technol Ther; 2024 Apr; 26(4):246-251. PubMed ID: 38133643
[No Abstract] [Full Text] [Related]
2. Use of Diabetes Technologies and Retinopathy in Adults With Type 1 Diabetes.
Liu TYA; Shpigel J; Khan F; Smith K; Prichett L; Channa R; Kanbour S; Jones M; Abusamaan MS; Sidhaye A; Mathioudakis N; Wolf RM
JAMA Netw Open; 2024 Mar; 7(3):e240728. PubMed ID: 38446483
[TBL] [Abstract][Full Text] [Related]
3. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes.
Lu J; Ma X; Zhou J; Zhang L; Mo Y; Ying L; Lu W; Zhu W; Bao Y; Vigersky RA; Jia W
Diabetes Care; 2018 Nov; 41(11):2370-2376. PubMed ID: 30201847
[TBL] [Abstract][Full Text] [Related]
4. Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy.
Rodbard D
Diabetes Obes Metab; 2023 Feb; 25(2):596-601. PubMed ID: 36314133
[TBL] [Abstract][Full Text] [Related]
5. Glycemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes.
Lu J; Ma X; Zhang L; Mo Y; Ying L; Lu W; Zhu W; Bao Y; Zhou J
J Diabetes Investig; 2019 May; 10(3):753-759. PubMed ID: 30306722
[TBL] [Abstract][Full Text] [Related]
6. Comparison of glucose time in range and area under curve in range in relation to risk of diabetic retinopathy in type 2 diabetes patients.
Wang Y; Lu J; Shen Y; Ni J; Zhang L; Lu W; Zhu W; Bao Y; Zhou J
J Diabetes Investig; 2022 Sep; 13(9):1543-1550. PubMed ID: 35435323
[TBL] [Abstract][Full Text] [Related]
7. Continuous glucose monitoring metrics following sub-Tenon's injection of triamcinolone acetonide for diabetic macular edema.
Sotani-Ogawa R; Kusuhara S; Hirota Y; Kim KW; Matsumiya W; Ogawa W; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):449-456. PubMed ID: 37864636
[TBL] [Abstract][Full Text] [Related]
8. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes.
Sartore G; Chilelli NC; Burlina S; Lapolla A
Acta Diabetol; 2013 Jun; 50(3):437-42. PubMed ID: 23417155
[TBL] [Abstract][Full Text] [Related]
9. Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes.
Dunn TC; Ajjan RA; Bergenstal RM; Xu Y
Diabetes Technol Ther; 2024 Mar; 26(3):203-210. PubMed ID: 38444315
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Daytime Versus Nighttime Continuous Glucose Monitoring Metrics with A1C in Adults with Type 1 Diabetes.
Shah VN; Akturk HK; Vigers T; Pyle L; Oliver N; Klonoff DC
Diabetes Technol Ther; 2023 Jan; 25(1):62-68. PubMed ID: 36306519
[No Abstract] [Full Text] [Related]
11. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
Krajnc M; Kravos Tramšek NA
Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
[TBL] [Abstract][Full Text] [Related]
12. Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes.
Yoo JH; Choi MS; Ahn J; Park SW; Kim Y; Hur KY; Jin SM; Kim G; Kim JH
Diabetes Technol Ther; 2020 Oct; 22(10):768-776. PubMed ID: 32167394
[No Abstract] [Full Text] [Related]
13. A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dL.
Beck RW; Raghinaru D; Calhoun P; Bergenstal RM
Diabetes Technol Ther; 2024 Mar; 26(3):151-155. PubMed ID: 37870460
[No Abstract] [Full Text] [Related]
14. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
Front Public Health; 2022; 10():990281. PubMed ID: 36091534
[TBL] [Abstract][Full Text] [Related]
15. Relationships between HbA1c and continuous glucose monitoring metrics of glycaemic control and glucose variability in a large cohort of children and adolescents with type 1 diabetes.
Piona C; Marigliano M; Mozzillo E; Rosanio F; Zanfardino A; Iafusco D; Maltoni G; Zucchini S; Piccinno E; Delvecchio M; Maffeis C
Diabetes Res Clin Pract; 2021 Jul; 177():108933. PubMed ID: 34216681
[TBL] [Abstract][Full Text] [Related]
16. Achieving the HbA1c Target Requires Longer Time in Range in Pregnant Women With Type 1 Diabetes.
Ling P; Yang D; Gu N; Xiao X; Lu J; Liu F; Zhou Z; Huang Q; Zhao J; Zhang M; Hu J; Luo S; Weng J; Yan J; Zheng X
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4309-e4317. PubMed ID: 34244734
[TBL] [Abstract][Full Text] [Related]
17. [The appropriate cut-off point of time in range (TIR) for evaluating glucose control in type 2 diabetes mellitus].
Dai DJ; Lu JY; Zhang L; Shen Y; Mo YF; Lu W; Zhu W; Bao YQ; Zhou J
Zhonghua Yi Xue Za Zhi; 2020 Oct; 100(38):2990-2996. PubMed ID: 33086449
[No Abstract] [Full Text] [Related]
18. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study.
De Meulemeester J; Charleer S; Visser MM; De Block C; Mathieu C; Gillard P
Diabetologia; 2024 May; ():. PubMed ID: 38787436
[TBL] [Abstract][Full Text] [Related]
19. Relationship of continuous glucose monitoring-related metrics with HbA1c and residual β-cell function in Japanese patients with type 1 diabetes.
Babaya N; Noso S; Hiromine Y; Taketomo Y; Niwano F; Yoshida S; Yasutake S; Kawabata Y; Ikegami H
Sci Rep; 2021 Feb; 11(1):4006. PubMed ID: 33597626
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.
Perais J; Agarwal R; Evans JR; Loveman E; Colquitt JL; Owens D; Hogg RE; Lawrenson JG; Takwoingi Y; Lois N
Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013775. PubMed ID: 36815723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
